Literature DB >> 2531420

Receptors for the Fc portion of immunoglobulin G (Fc gamma R) on human monocytes and macrophages.

P G Comber1, F Gomez, M D Rossman, A D Schreiber.   

Abstract

Human mononuclear phagocytes bear a group of cell surface receptors that bind the Fc domain of IgG. These Fc gamma receptors are utilized in the phagocytosis of opsonized cells and immune complexes and are involved in the pathogenesis of several hematologic and immunologic disorders. However, the relative contributions of the different Fc gamma receptors to these processes is uncertain. The expression of these receptors can also be modulated by several physiologic and pharmacologic factors, including IFN-gamma and glucocorticoids, but the mechanisms of this modulation have not been fully elucidated. The recent isolation of molecular probes for these receptors should allow a more complete understanding of the function of these molecules and their response to modulatory signals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2531420

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  5 in total

Review 1.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

Review 2.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 3.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

4.  In vivo glucocorticoid modulation of guinea pig splenic macrophage Fc gamma receptors.

Authors:  P Ruiz; F Gomez; M King; R Lopez; C Darby; A D Schreiber
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 5.  New developments in atherosclerosis: clinical potential of PCSK9 inhibition.

Authors:  Ilaria Giunzioni; Hagai Tavori
Journal:  Vasc Health Risk Manag       Date:  2015-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.